A novel liquid biopsy assay for detection of ERBB2 (HER2) amplification in circulating tumor cells (CTCs)

Journal of Circulating Biomarkers · Published 2024-10-04 · DOI 10.33393/jcb.2024.3046

Authors being retrieved — see the publisher record. https://doi.org/10.33393/jcb.2024.3046

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Value of clinical laboratory test for early prediction of mortality in patients with COVID-19: the BGM score · Journal of Circulating Biomarkers · 2021 · Same journal
• Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer · Journal of Circulating Biomarkers · 2020 · Same journal
• Strategies for enumeration of circulating microvesicles on a conventional flow cytometer Counting beads and scatter parameters · Journal of Circulating Biomarkers · 2018 · Same journal
• Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor · Journal of Circulating Biomarkers · 2025 · Same journal
• Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease · Journal of Circulating Biomarkers · 2022 · Same journal
• Soluble IL-33 receptor predicts survival in acute kidney injury · Journal of Circulating Biomarkers · 2022 · Same journal
• Impact of clinico-biochemical variations on the etiopathogenesis of cataract: a case-control study · Journal of Circulating Biomarkers · 2023 · Same journal
• Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates · Journal of Circulating Biomarkers · 2021 · Same journal
• Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential · Journal of Circulating Biomarkers · 2019 · Same journal
• Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection · Journal of Circulating Biomarkers · 2022 · Same journal